Skip to main content
Adocia logo

Adocia — Investor Relations & Filings

Ticker · ADOC ISIN · FR0011184241 LEI · 969500ZL79KYH9PTYP78 PA Real estate activities
Open in API
Filings indexed 826 across all filing types
Latest filing 2016-05-13 AGM Information
Country FR France
Listing PA ADOC

About Adocia

https://www.adocia.com

Adocia is a clinical-stage biotechnology company that specializes in developing innovative treatments for metabolic diseases, with a primary focus on diabetes and obesity. The company's core expertise is the development of novel formulations of approved peptides, proteins, and metabolic hormones, such as insulin, to improve their therapeutic efficacy. Adocia leverages proprietary technology platforms to create a pipeline of specialty products. Its research also extends to novel cell therapy approaches, including an immunoprotective scaffold for cell delivery. The company's business model involves advancing its product candidates to clinical proof-of-concept before licensing them to partners for late-stage development and commercialization.

Recent filings

Filing Released Lang Actions
Communiqués en période d’offre / Autres communiqués
AGM Information Classification · 1% confidence The document is explicitly titled "COMMUNIQUE DE PRESSE" (Press Release) and announces the date, time, and location for the company's "assemblée générale annuelle" (Annual General Meeting or AGM). It details the publication of the notice of meeting (avis de réunion valant convocation) in the BALO and provides instructions for shareholder participation and voting. Since the document is an announcement *about* the upcoming AGM, rather than the voting results (DVA) or the proxy materials themselves (PSI), the most appropriate classification is AGM Information (AGM-R), which covers presentations and materials shared during the AGM, or potentially a general announcement if it were less specific. Given the explicit mention of the AGM date and the associated convocation notice, AGM-R is the best fit, although it is an announcement *of* the meeting, which sometimes overlaps with RPA/RNS. However, because the core subject is the AGM event itself, AGM-R is prioritized over a generic announcement.
2016-05-13 French
Communications during bidding periods / Other releases
Legal Proceedings Report Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and announces specific corporate news: the granting of new patents for the BioChaperone Combo product in Europe and the US. It details the patent numbers, expiration dates, and strategic implications. This type of announcement, focusing on intellectual property milestones, is typically classified as a general corporate update or regulatory filing, but given the options, it is not a formal financial report (10-K, IR, ER, MRQ) nor a management/board change (MANG). It is a specific announcement of a corporate event (patent grant). Since there is no specific code for 'Patent Announcement', and it is a formal press release detailing a significant corporate development, it fits best under the general 'Regulatory Filings' (RNS) category, which serves as a fallback for miscellaneous official announcements that aren't covered by the more specific financial or governance codes. It is not an announcement of a report publication (RPA) as it contains the substance of the news itself, not just a notice that a report is available.
2016-05-03 English
Communiqués en période d’offre / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces the granting of patents related to the company's product, BioChaperone Combo. It details the patent numbers, jurisdictions (Europe, US), and the implications for the product pipeline. This type of announcement, focusing on intellectual property protection and business updates via a press release format, is generally classified as a general business update or regulatory filing. Since it is not a formal financial report (10-K, IR, ER, MRQ), nor a specific management/board change (MANG), nor a dividend notice (DIV), nor a proxy statement (DEF 14A/PSI), the most appropriate category is the general regulatory announcement/miscellaneous filing category, RNS, as it is a formal communication to the market about a significant corporate event (patent grant). The length (8778 chars) is substantial, so it is not an RPA.
2016-05-03 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 1% confidence The document is explicitly labeled as a "PRESS RELEASE" announcing "positive topline results" from a Phase 1b clinical study involving two pharmaceutical companies (Adocia and Lilly). This type of announcement, detailing preliminary clinical trial outcomes, is characteristic of an Earnings Release (ER) or a general announcement related to company performance/pipeline updates. Since it is a press release announcing key financial/operational results (clinical trial success), it fits best under the Earnings Release (ER) category, which covers initial announcements of periodical results/key highlights. It is not a full Annual Report (10-K), a comprehensive Interim Report (IR), a Call Transcript (CT), or a specific regulatory filing like DIRS or DEF 14A. Given the nature of reporting clinical trial milestones, ER is the most appropriate fit among the provided options for a high-level, immediate announcement.
2016-04-27 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Earnings Release Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces the positive primary results of a Phase 1b clinical study for a drug candidate (BioChaperone Lispro). It details clinical findings, safety profiles, and includes forward-looking statements and contact information for both companies involved (Adocia and Eli Lilly). This format is characteristic of an initial announcement of financial or operational results, specifically clinical trial outcomes, which typically precedes a more comprehensive report. Given the options, this is best classified as an Earnings Release (ER) as it is the initial announcement of key performance/result highlights, even though it pertains to clinical data rather than quarterly revenue. It is not a full transcript (CT), a comprehensive interim report (IR), or a formal regulatory filing like a 10-K. Since it is a direct announcement of results, ER is the most appropriate fit among the provided codes for a press release detailing key performance indicators (clinical outcomes). FY 2016
2016-04-27 French
Communicated under the obligation to provide permanent information / Communication relating to accounts, results, and turnover
Earnings Release Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and begins by announcing "Adocia announces first quarter 2016 results". It provides key financial highlights (revenue, cash position) for the three months ending March 31, 2016, including unaudited tables comparing Q1 2016 to Q1 2015. This content structure—a brief announcement of period-specific financial performance—is the definition of an Earnings Release (ER). It is not a comprehensive Annual Report (10-K) or a detailed Interim/Quarterly Report (IR), but rather the initial summary release. Q1 2016
2016-04-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.